Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 12.9% | 269.4% | 899.7% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 92.3% | 97.3% | 87.7% | -81.7% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 14% | 19.9% | -213.2% | -3,953.5% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -1.9% | 1.6% | -283.3% | -4,709.9% |
| EPS Diluted | -0.03 | 0.022 | -1.03 | -2.41 |
| % Growth | -239.5% | 102.1% | 57.3% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |